Results 151 to 160 of about 2,034,935 (392)

Model‐informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims This study aimed to develop and validate a population pharmacokinetic‐pharmacodynamic (pop‐PK‐PD) model to describe carboplatin‐induced myelosuppression in cancer patients and support dose individualization. Methods Data from 580 cancer patients treated with carboplatin at Amsterdam UMC between 2019 and 2022 were used for model ...
Alessandro De Carlo, Elena Maria Tosca, Mirjam Crul, Tim Schutte, Lia van Zuijlen, Idris Bahce, Medhat M. Said, Jan Buter, Harmen Huls, Paolo Magni, Imke Bartelink   +10 more
wiley   +1 more source

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Clinical Pharmacology &Therapeutics, EarlyView.
We present model‐informed selection of the recommended dose for expansion (RDE) of investigational oral ATR inhibitor tuvusertib, by integrating clinical pharmacokinetics (PK), pharmacodynamics (PD), and safety data from DDRiver Solid Tumors 301 trial Part A1 (NCT04170153).
Jatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann, Timothy A. Yap, Ruth Plummer, Anthony W. Tolcher, Johann S. de Bono, Ioannis Gounaris, Zoltan Szucs, Astrid Zimmermann, Irina Kareva, Jayaprakasam Bolleddula, Annick Seithel‐Keuth, Giuseppe Locatelli, Marta Enderlin, Christine Hicking, Anup Zutshi, Wei Gao, Rainer Strotmann, Lisa Benincosa, Karthik Venkatakrishnan   +20 more
wiley   +1 more source

Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia

Haematologica, 2017
Primary immune thrombocytopenia is an autoimmune disorder characterized by increased platelet destruction and insufficient platelet production without another identified underlying disorder.
Douglas B. Cines, Jeffrey Wasser, Francesco Rodeghiero, Beng H. Chong, Michael Steurer, Drew Provan, Roger Lyons, Jaime Garcia-Chavez, Nancy Carpenter, Xuena Wang, Melissa Eisen   +10 more
doaj   +1 more source

Understanding how older age drives decision‐making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients [PDF]

, 2018
Francesca Palandri, Lucia Catani, Giuseppe Auteri, Daniela Bartoletti, Sofia Fatica, Alessio Fusco, Maria Letizia Bacchi Reggiani, Michèle Cavo, Nicola Vianelli   +8 more
openalex   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Clinical and Laboratory Analysis of Children Who Follow Up with Thrombocytopenia: A Retrospective Study

Güncel Pediatri
Introduction: Platelets are cells that play an important role in the first phase of hemostasis, where the clot plug is formed. Disorders in the number or function of platelets can lead to bleeding.
Yasemin Denkboy Öngen, Birol Baytan
doaj   +1 more source

Immune Thrombocytopenia in Children

Zdorovʹe Rebenka, 2013
.
L. Ya. Dubey, O.O. Troyanovskaya, I.P. Tsymbaliuk, O.I. Dorosh, N.V. Dubey, M.V. Sapuzhak   +5 more
doaj   +1 more source

Inherited metabolic epilepsies–established diseases, new approaches

Epilepsia Open, EarlyView.
Abstract Inherited metabolic epilepsies (IMEs) represent the inherited metabolic disorders (IMDs) in which epilepsy is a prevailing component, often determining other neurodevelopmental outcomes associated with the disorder. The different metabolic pathways affected by individual IMEs are the basis of their rarity and heterogeneity.
Itay Tokatly Latzer, Phillip L. Pearl
wiley   +1 more source

Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura : A Single Technology Appraisal [PDF]

, 2008
Evidence Review Group (ERG) final report for the National Institute for Health and Clinical ExcellencePublisher ...
Boyers, Dwayne, Crowther, M, Fraser, Cynthia Mary, Jenkinson, David James, Jia, Xueli, Mowatt, Graham   +5 more
core  

Vaccine‐induced immune thrombosis and thrombocytopenia syndrome following adenovirus‐vectored severe acute respiratory syndrome coronavirus 2 vaccination: a novel hypothesis regarding mechanisms and implications for future vaccine development [PDF]

, 2021
Paul Monagle, Ashley P. Ng, Matthew D. Linden, Vera Ignjatović, Alison Farley, Samir Taoudi, Sant Rayn Pasricha, Joseph Torresi   +7 more
openalex   +1 more source